Replay Conf call - Janssen deal & Replay Webcast - ITP Ph2 & AML Ph1/2 data

2011

arGEN-X raises EUR 27.5 million (USD 37 million) in oversubscribed Series B round

December 01, 2011

  • Funds will be used to progress differentiated therapeutic antibody programs into clinical development

Rotterdam, the Netherlands and Ghent, Belgium – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announced today the closing of a EUR 27.5 million (USD 37 million) Series B fundraising round, which was oversubscribed. The fundraising was co-led by OrbiMed Advisors (USA) and Seventure Partners (France), with the existing shareholders Forbion Capital Partners, Credit Agricole Private Equity, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB also participating. OrbiMed’s founding partner, Dr Mike Sheffery, will join the arGEN-X Supervisory Board.

arGEN-X is awarded €1.3 million IWT Grant to Advance Proprietary SIMPLE Antibody™ Platform for Addressing Challenging Disease Targets

November 30, 2011

Rotterdam, The Netherlands – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announced today it has received a grant of €1.3 million to further advance its powerful discovery platform for addressing challenging disease targets. The grant was awarded by the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT), and is the third award the Company has received from the institute, totalling €4.1 million to date.

arGEN-X presents significant progress at Biopharm America 2011

September 07, 2011

  • SIMPLE Antibody™ platform continues to demonstrate clear advantages in therapeutic antibody discovery

Rotterdam, the Netherlands – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies using its proprietary SIMPLE Antibody™ platform, will provide an update on this year’s significant corporate progress during a presentation by its CEO Tim Van Hauwermeiren at the BioPharm America conference in Boston, MA, USA (www.ebdgroup.com/bpa/).

arGEN-X announces non-exclusive license with BioWa for Potelligent® technology

July 26, 2011

  • SYNERGISTIC EFFECT OF APPLYING POTELLIGENT® TO SIMPLE ANTIBODIES™ CREATES BEST-IN-CLASS ANTIBODY THERAPEUTICS

Rotterdam, the Netherlands; Ghent, Belgium; Princeton, NJ, USA – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announces it has signed a non-exclusive license agreement with BioWa Inc., the exclusive worldwide licensor of POTELLIGENT® Technology.

arGEN-X initiates a second pre-clinical development program in under 18 months from start of operations

May 16, 2011

  • ARGX-110 TO TARGET AUTOIMMUNE, INFLAMMATION AND ONCOLOGY INDICATIONS

Rotterdam, the Netherlands and Ghent, Belgium – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announces that it has progressed ARGX-110, its second therapeutic candidate, into formal pre-clinical development in less than 18 months since the Company began its operations.

arGEN-X signs discovery and development alliance with Lilly

January 05, 2011

Rotterdam, The Netherlands – arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody™ platform, today announced it has entered into an alliance with Eli Lilly and Company (“Lilly”) to discover and develop novel therapeutic antibody products against targets submitted by Lilly.